Literature DB >> 31560233

Role of pentraxin-3 in risk assessment of patients with metabolic syndrome.

A Zlibut1, I C Bocsan2, R M Pop2, S C Vesa2, K Bheecarry1, R Revnic3, B Cojan-Minzat1, S Lupu4, A D Buzoianu2, L Agoston-Coldea1.   

Abstract

BACKGROUND: Inflammation plays a major role in the development of metabolic syndrome (MetS) and its progression. Recent studies have shown that pentraxin-3 (PTX-3), osteoprogerin (OPG), and tumor necrosis factor-alpha (TNF-α) are key factors in MetS pathophysiology, but evidence for endorsing their clinical use is currently unclear and insufficient. AIM: The study aimed to evaluate the association between the inflammatory biomarkers' levels and the severity of MetS.
METHODS: The study was observational, transversal, prospective, cohort, and analytical type. We enrolled 80 patients (M:F = 1, mean age = 55 ± 10.77 years) who met MetS criteria. The study protocol included: medical history, physical examination, 6-min walk test distance (6MWTD), biochemical tests, electrocardiogram, echocardiography, and carotid ultrasonography. We also performed plasmatic measurement of PTX-3, OPG, and TNF-α, in addition to standard biochemical tests.
RESULTS: Subjects with severe MetS had higher values of body mass index (BMI) and waist circumference (p < 0.001, p = 0.001). PTX-3 levels were significantly higher in patients with severe MetS (p = 0.03) and the values were not influenced by age or gender. OPG positively correlated with BMI (r = 0.264, p = 0.018). 6MWTD was lower in patients with severe MetS (p = 0.005), whereas CCA-IMT was higher in this group of patients (p = 0.005). In addition, the receiver operating characteristic (ROC) curve analysis for PTX-3 identified a cut-off value of 10.7 ng/dl that differentiates between mild and severe MetS [AUC 0.656; sensitivity =47.1% (95% CI = 36.1%-62.3%); specificity = 78.9% (95% CI = 54.4%-93.9%)].
CONCLUSION: PTX-3 was correlated with the severity of MetS, with other inflammatory parameters and cardiovascular tests. CCA-IMT and 6MWTD are useful in differentiating between mild and severe MetS.

Entities:  

Keywords:  atherosclerosis; metabolic syndrome; osteoprotegerin; pentraxin-3; tumor necrosis factor-alpha

Mesh:

Substances:

Year:  2019        PMID: 31560233     DOI: 10.1556/2060.106.2019.18

Source DB:  PubMed          Journal:  Physiol Int        ISSN: 2498-602X            Impact factor:   2.090


  1 in total

Review 1.  The Role of PTX3 in Mineralization Processes and Aging-Related Bone Diseases.

Authors:  Umberto Tarantino; Chiara Greggi; Ida Cariati; Virginia Veronica Visconti; Monica Gasparini; Marco Cateni; Elena Gasbarra; Annalisa Botta; Antonietta Salustri; Manuel Scimeca
Journal:  Front Immunol       Date:  2021-01-29       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.